Anti-Commercial Bribery Compliance in China: Lessons from the GSK Case

Anti-bribery enforcement in China has intensified significantly in recent years, creating substantial compliance challenges for both domestic and foreign companies operating in the country. Unlike some Western jurisdictions that have specific anti-bribery statutes, China's legal framework for combating commercial bribery is spread across multiple laws, including the PRC Anti-Unfair Competition Law and the PRC Criminal Law. Understanding this framework and learning from high-profile enforcement actions is essential for any business operating in China.

The Anti-Unfair Competition Law prohibits business operators from giving bribes in the form of property or other means for the purpose of selling or purchasing products. This broad prohibition covers not only cash payments but also gifts, entertainment, travel, and other benefits provided to influence business decisions. The law applies to all business operators in China, including domestic companies, sino-foreign joint ventures, wholly foreign-owned enterprises, and representative offices of foreign companies.

The PRC Criminal Law criminalizes the act of giving money or property to any employee of a company or enterprise for the purpose of seeking illegitimate benefits. Criminal penalties for bribery can include fines, confiscation of property, imprisonment, or detention. Individuals who are directly in charge of or directly responsible for the offense face the most severe penalties. The Criminal Law also contains specific provisions addressing bribery of government officials, which carry enhanced penalties.

In February 2011, the Chinese government extended the coverage of the Criminal Law to prohibit Chinese nationals and Chinese companies from paying bribes to government officials outside China. This extraterritorial application of Chinese anti-bribery law reflects China's growing role in international commerce and its commitment to combating corruption on a global scale. Chinese companies with overseas operations must now ensure compliance with both Chinese and local anti-bribery laws in the jurisdictions where they operate.

Foreign companies operating in China must also consider the applicability of international anti-bribery regimes. The US Foreign Corrupt Practices Act (FCPA) applies to non-US companies that have a US nexus, such as SEC registration or securities listed on US exchanges. The UK Bribery Act has even broader reach, potentially applying to the global operations of any business with a UK presence. Both statutes have become key enforcement priorities for their respective regulators, significantly raising the risks for companies within their jurisdiction.

China has also signed the 1997 OECD Anti-Bribery Convention, joining 38 other countries committed to curbing bribery of foreign officials in international business transactions. This convention requires signatory countries to enact legislation criminalizing the bribing of foreign public officials and to enforce those laws effectively. China's participation in this convention demonstrates its commitment to aligning its anti-bribery framework with international standards.

The GlaxoSmithKline scandal provides a powerful case study in the consequences of non-compliance with Chinese anti-bribery laws. Chinese authorities detained GSK employees and medical personnel, including four senior Chinese executives connected to the scandal. The detained executives included the company's Chinese legal director, highlighting the personal risk faced by corporate officers when compliance systems fail. GSK ultimately agreed to pay a record fine of 5 billion yuan (approximately $800 million) to resolve the case.

There are two critical trends demonstrated by the GSK case. First, foreign companies can expect continued and increased enforcement of Chinese anti-corruption laws against them. Chinese regulators have demonstrated both the capability and the will to pursue complex, high-profile cases involving multinational corporations. Second, local Chinese lawyers, including compliance counsel and compliance specialists, must be able to perform their jobs independently and without fear of retaliation from local management. The case demonstrated the dangers of compliance functions being co-opted by business objectives.

Companies seeking to mitigate their bribery risk in China should implement robust compliance programs tailored to the specific risks of their industry and operations. Key elements of an effective program include written policies and procedures, regular employee training, due diligence on third-party agents and business partners, internal reporting mechanisms, and periodic auditing and monitoring. Compliance should be embedded in business processes rather than treated as a separate function.

In conclusion, the anti-bribery compliance landscape in China has become increasingly challenging for companies of all sizes and industries. The consequences of non-compliance can be severe, including criminal prosecution, substantial fines, reputational damage, and exclusion from government contracts. By understanding the legal framework, learning from enforcement cases, and implementing robust compliance programs, companies can protect themselves and their employees from the substantial risks associated with commercial bribery in China.